Letters

od Kaminski, Mark
Wydane 1991

Complexity and Expressive Power of Weakly Well-Designed SPARQL

od Kaminski, Mark, Kostylev, Egor V.
Wydane w Theory Comput Syst (2017)

Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study

od Dewaraja, Yuni K., Wilderman, Scott J., Koral, Kenneth F., Kaminski, Mark S., Avram, Anca M.
Wydane 2009

Prediction of Therapy Tumor-Absorbed Dose Estimates in I-131 Radioimmunotherapy Using Tracer Data Via a Mixed-Model Fit to Time Activity

od Schipper, Matthew J., Koral, Kenneth F., Avram, Anca M., Kaminski, Mark S., Dewaraja, Yuni K.
Wydane 2012

Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia

od Kujawski, Lisa, Ouillette, Peter, Erba, Harry, Saddler, Chris, Jakubowiak, Andrzej, Kaminski, Mark, Shedden, Kerby, Malek, Sami N.
Wydane 2008

Biological-Effect Modeling of Radioimmunotherapy for Non-Hodgkins Lymphoma: Determination of Model Parameters

od Roberson, Peter L., Wilderman, Scott J., Avram, Anca M., Kaminski, Mark S., Schipper, Matthew J., Dewaraja, Yuni K.
Wydane 2014

Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy

od Girard, Jennifer, Reneau, John, Devata, Sumana, Wilcox, Ryan A, Kaminski, Mark S, Mercer, Jessica, Carty, Shannon, Phillips, Tycel J
Wydane w Onco Targets Ther (2019)

Bio-effect model applied to (131)I radioimmunotherapy of refractory non-Hodgkin’s lymphoma

od Roberson, Peter L., Amro, Hanan, Wilderman, Scott J., Avram, Anca M., Kaminski, Mark S., Schipper, Matthew J., Dewaraja, Yuni K.
Wydane 2010

Survival Following Salvage Therapy for Primary Refractory Peripheral T-Cell Lymphomas (PTCL)

od Zhang, Janie Y., Briski, Robert, Devata, Sumana, Kaminski, Mark S., Phillips, Tycel J., Mayer, Tera L., Bailey, Nathanael G., Wilcox, Ryan A.
Wydane w Am J Hematol (2017)

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia

od Ouillette, Peter, Collins, Roxane, Shakhan, Sajid, Li, Jinghui, Peres, Edward, Kujawski, Lisa, Talpaz, Moshe, Kaminski, Mark, Li, Cheng, Shedden, Kerby, Malek, Sami N.
Wydane 2011

Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma

od Roberson, Peter L., Smith, Lauren B., Morgan, Meredith A., Schipper, Matthew J., Wilderman, Scott J., Avram, Anca M., Kaminski, Mark S., Dewaraja, Yuni K.
Wydane w Cancer Biother Radiopharm (2017)

A Single Center Phase II Study of Ixazomib in Patients with Relapsed or Refractory Cutaneous or Peripheral T-cell Lymphomas

od Boonstra, Philip S., Avery, Polk, Brown, Noah, Hristov, Alexandra C., Bailey, Nathanael G., Kaminski, Mark S., Phillips, Tycel, Devata, Sumana, Mayer, Tera, Wilcox, Ryan A.
Wydane w Am J Hematol (2017)

A PATHOBIOLOGICAL ROLE OF THE INSULIN RECEPTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA

od Saiya-Cork, Kamlai, Collins, Roxane, Parkin, Brian, Ouillette, Peter, Kuizon, Erlene, Kujawski, Lisa, Erba, Harry, Campagnaro, Erica, Shedden, Kerby, Kaminski, Mark, Malek, Sami N.
Wydane 2011

(131)I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling

od Dewaraja, Yuni K., Schipper, Matthew J., Roberson, Peter L., Wilderman, Scott J., Amro, Hanan, Regan, Denise D., Koral, Kenneth F., Kaminski, Mark S., Avram, Anca M.
Wydane 2010

Follicular lymphoma-associated BTK mutations are inactivating resulting in augmented AKT activation

od Hu, Nan, Wang, Fangyang, Sun, Tianyu, Xu, Zhengfan, Zhang, Jing, Bernard, Denzil, Xu, Shilin, Wang, Shaomeng, Kaminski, Mark, Devata, Suma, Phillips, Tycel, Malek, Sami N.
Wydane w Clin Cancer Res (2021)

Recurrent mutations in the MTOR regulator RRAGC in follicular lymphoma

od Ying, Zhang Xiao, Jin, Meiyan, Peterson, Luke F., Bernard, Denzil, Saiya-Cork, Kamlai, Yildiz, Mehmet, Wang, Shaomeng, Kaminski, Mark S., Chang, Alfred E., Klionsky, Daniel J., Malek, Sami N.
Wydane w Clin Cancer Res (2016)

Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy

od Dewaraja, Yuni K., Schipper, Matthew J., Shen, Jincheng, Smith, Lauren B., Murgic, Jure, Savas, Hatice, Youssef, Ehab, Regan, Denise, Wilderman, Scott J., Roberson, Peter L., Kaminski, Mark S., Avram, Anca M.
Wydane w J Nucl Med (2014)

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0433

od Friedberg, Jonathan W., Unger, Joseph M., Burack, W. Richard, Gopal, Ajay K., Raju, Robert N., Nademanee, Auayporn P., Kaminski, Mark S., Li, Hongli, Press, Oliver W., Miller, Thomas P., Fisher, Richard I.
Wydane 2014

Activating STAT6 mutations in follicular lymphoma

od Yildiz, Mehmet, Li, Hongxiu, Bernard, Denzil, Amin, Nisar A., Ouillette, Peter, Jones, Siân, Saiya-Cork, Kamlai, Parkin, Brian, Jacobi, Kathryn, Shedden, Kerby, Wang, Shaomeng, Chang, Alfred E., Kaminski, Mark S., Malek, Sami N.
Wydane w Blood (2015)

Follicular lymphoma–associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR

od Wang, Fangyang, Gatica, Damián, Ying, Zhang Xiao, Peterson, Luke F., Kim, Peter, Bernard, Denzil, Saiya-Cork, Kamlai, Wang, Shaomeng, Kaminski, Mark S., Chang, Alfred E., Phillips, Tycel, Klionsky, Daniel J., Malek, Sami N.
Wydane w J Clin Invest (2019)